Kainova Therapeutics
Latest round
- Series B
Last raised
- Feb 2026
Total raised
- $52M
Investors
- 24
About Kainova Therapeutics
a., is focused on developing innovative therapies targeting G protein-coupled receptors (GPCRs) to meet unmet medical needs in immuno-oncology and inflammation. Founded in 2008 in Strasbourg, France by Pascal Neuville, Kainova Therapeutics Inc. develops GPCR-targeting therapies. The company has successfully navigated changes in strategy and has established partnerships with various pharmaceutical companies. In February 2026, Kainova Therapeutics Inc. The CEO, Pascal Neuville, has been instrumental in guiding the company's operations since its inception, while founder Anggi Febrianty has played a pivotal role in its establishment. Domain Therapeutics specializes in developing GPCR-targeting therapies aimed at addressing significant medical needs in immuno-oncology and inflammation. Their proprietary candidates include DT-9081, an EP4 receptor antagonist, DT-7012, an anti-CCR8 depleting antibody, and DT-9046, a biased antagonist of PAR2. These therapies are meticulously crafted to enhance efficacy and improve patient outcomes by modulating the immune system. The company aims to deliver solutions in markets across North America and Europe, providing therapeutic products to pharmaceutical companies, healthcare providers, and patients.30 and an EBITDA of EUR -15,390,268. The company generates revenue primarily through partnerships with leading pharmaceutical firms, which may involve collaborative research, licensing agreements, and milestone payments. Their core therapeutic offerings, including DT-7012 and DT-9046, are integral to their revenue structure, designed to support further investment and partnerships as they advance to clinical stages.
Who invested in Kainova Therapeutics
24 investors across 5 rounds
See all investors in Kainova Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Kainova Therapeutics
Who invested in Kainova Therapeutics?
Kainova Therapeutics has 24 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kainova Therapeutics raised?
Kainova Therapeutics has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Kainova Therapeutics last raise money?
Kainova Therapeutics's most recent round on record is a Series B, in Feb 2026.
What does Kainova Therapeutics do?
Kainova Therapeutics is a biotechnology company.
Where is Kainova Therapeutics headquartered?
Kainova Therapeutics is headquartered in Montreal, Canada.
Which VCs invest in companies like Kainova Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Kainova Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Kainova Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.